{
    "Trade/Device Name(s)": [
        "TheraTest EL-anti-CCP/2TM"
    ],
    "Submitter Information": "TheraTest Laboratories, Inc.",
    "510(k) Number": "K090753",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NHX"
    ],
    "Summary Letter Date": "March 3, 2010",
    "Summary Letter Received Date": "March 3, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.5775"
    ],
    "Regulation Name(s)": [
        "Rheumatoid factor immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG autoantibodies to cyclic citrullinated peptide (CCP)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)"
    ],
    "Methodologies": [
        "Autoantibody detection"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for TheraTest EL-anti-CCP/2TM ELISA test for detection of IgG autoantibodies to CCP in human serum as an aid in rheumatoid arthritis diagnosis",
    "Indications for Use Summary": "Intended for use in clinical laboratories as an in vitro diagnostic test to detect and measure IgG autoantibodies to cyclic citrullinated peptide in human serum by ELISA, aiding in rheumatoid arthritis diagnosis in conjunction with other findings",
    "fda_folder": "Immunology"
}